1. Home
  2. ACET vs MCHX Comparison

ACET vs MCHX Comparison

Compare ACET & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.98

Market Cap

79.9M

Sector

Health Care

ML Signal

HOLD

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

HOLD

Current Price

$1.76

Market Cap

67.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACET
MCHX
Founded
1947
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
79.9M
67.3M
IPO Year
2017
2003

Fundamental Metrics

Financial Performance
Metric
ACET
MCHX
Price
$7.98
$1.76
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$48.33
N/A
AVG Volume (30 Days)
89.6K
21.9K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$90,291,000.00
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$1.32
52 Week High
$9.47
$2.14

Technical Indicators

Market Signals
Indicator
ACET
MCHX
Relative Strength Index (RSI) 43.58 58.55
Support Level $7.78 $1.55
Resistance Level $8.68 $1.92
Average True Range (ATR) 0.51 0.11
MACD -0.09 -0.00
Stochastic Oscillator 7.52 66.67

Price Performance

Historical Comparison
ACET
MCHX

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

Share on Social Networks: